GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect & identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, & state-of-the-art computer science & data science to enhance the scientific understanding of cancer biology, & to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, & the United Kingdom. GRAIL is a wholly-owned subsidiary of Illumina (NASDAQ:ILMN). For more information, please visit www.grail.com
Detect cancer, when it can be cured at GRAIL!
This role is geared towards assessing the potential of novel analytes/biomarkers in blood & other biofluids for improving cancer detection both in the early detection & post-diagnostic space. You will be part of a multifaceted technical team that owns the scientific direction of future GRAIL products. You will have access to rich, clinically relevant datasets from internal GRAIL studies & collaborators in academia. As a computational biologist/bioinformatics scientist within the New Products team, your experience will span the entire scientific lifecycle - from study design to data analysis to presenting results to relevant collaborators. Your work will result in exciting discoveries in cancer biology, impactful publications, & products for the early detection of or support for patients with cancer.